thalidomide has been researched along with ixazomib in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (61.11) | 24.3611 |
| 2020's | 14 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Appel, A | 1 |
| Abe, M; Fujii, S | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H | 1 |
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Boccadoro, M; Bonello, F; Larocca, A; Salvini, M | 1 |
| Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T | 1 |
| Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
| de Wit, E; Moreau, P | 1 |
| Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L | 1 |
| Guo, H; Sun, X; Wang, B; Xu, W | 1 |
| Costello, C; Mikhael, JR | 1 |
| Boccadoro, M; Giudice, D; Larocca, A; Pautasso, C; Salvini, M; Troia, R | 1 |
| Corvatta, L; Gentili, S; Offidani, M | 1 |
| Joseph, NS; Kaufman, JL | 1 |
| Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A | 1 |
| Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Hinke, A; Jelinek, T; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Meckl, A; Melchardt, T; Niederwieser, D; Nolte, S; Petzer, A; Pönisch, W; Pour, L; Rumpold, H; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N | 1 |
| Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Melchardt, T; Niederwieser, D; Petzer, A; Poenisch, W; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X | 1 |
| Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K | 1 |
| Abildgaard, N; Axelsson, P; Blimark, C; Hansson, M; Haukas, E; Hieu Do, T; Klein, SK; Klostergaard, A; Knut-Bojanowska, D; Levin, MD; Leys, RBL; Mellqvist, UH; Poddighe, PJ; Salomo, M; Schjesvold, FH; Sonneveld, P; Stege, CAM; Stevens-Kroef, M; Svirskaite, A; Szatkowski, D; van de Donk, NWCJ; van der Holt, B; van der Spek, E; Waage, A; Ypma, PF; Zweegman, S | 1 |
| Bergin, K; Kalff, A; Reynolds, J; Sirdesai, S; Spencer, A; Wallington-Beddoe, C; Yuen, F | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
10 review(s) available for thalidomide and ixazomib
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide | 2018 |
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Boron Compounds; Dexamethasone; Glycine; Half-Life; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Salvage Therapy; Thalidomide; Tissue Distribution | 2018 |
Triplet vs. doublet drug regimens for managing multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Glycine; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide | 2018 |
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Magnetic Resonance Imaging; Prognosis; Thalidomide | 2018 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
15 trial(s) available for thalidomide and ixazomib
| Article | Year |
|---|---|
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Proteasome Inhibitors; Safety; Survival Rate; Thalidomide | 2014 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Exanthema; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Quality of Life; Thalidomide; Thrombocytopenia | 2016 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; China; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Placebo Effect; Thalidomide | 2017 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide | 2017 |
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Survival Rate; Thalidomide | 2019 |
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Glycine; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2020 |
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-1
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Physicians; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2022 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
11 other study(ies) available for thalidomide and ixazomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Health Care Costs; Health Resources; Hospitalization; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Portugal; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2019 |
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Multiple Myeloma; Quality of Life; Thalidomide | 2020 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Diarrhea; Glycine; Humans; Japan; Leukopenia; Middle Aged; Multiple Myeloma; Product Surveillance, Postmarketing; Thalidomide; Thrombocytopenia | 2022 |